This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Common variable immunodeficiency with predominant immunoregulatory T-cell disorders — CVID Type II현저한 면역조절T-세포장애에 의한 공통 가변성 면역결핍

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D83.1 (common variable immunodeficiency with predominant immunoregulatory T-cell disorders) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsCommon variable immunodeficiency (CVID) with T-cell regulatory disorder, CVID with immunoregulatory T-cell abnormality, CVID Type II, hypogammaglobulinemia with T-cell regulatory abnormality
C. Adult onsetPossibility of first onset in adulthood: high — the CVID subtype due to T-cell abnormalities is commonly first diagnosed in adulthood through autoimmune complications (thrombocytopenia, hemolytic anemia) or recurrent infections; granulomatous complications are also diagnosed in adulthood.
1. HistoryShares the overall history of CVID (after Bruton in 1953 → CVID concept → classification of the T-cell abnormality subtype): 1999 ESID/PAGID criteria; the EUROClass study (2008) identified the association of CD21lo B cells and Treg abnormalities with T-cell regulatory abnormalities.
2. CausesAbnormal T-cell helper function, Tfh cell deficiency and regulatory T-cell (Treg) dysfunction are the main causes. T-cell regulatory abnormalities are prominent in ICOS deficiency, LRBA deficiency and CTLA-4 haploinsufficiency. Reduced CD4+ T-cell numbers and impaired Tfh differentiation.
3. GeneticsAssociated with variants in ICOS (2q33.2), LRBA (4q31.3), CTLA4 (2q33.2), NFKB1 and NFKB2. ICOS and LRBA: autosomal recessive; CTLA-4: autosomal dominant. The rate of identifying a single-gene cause tends to be higher in the group with prominent T-cell abnormalities.
4. General epidemiologyWithin CVID as a whole (1:25,000–1:50,000), the subtype with predominant T-cell abnormalities is estimated at about 20–30%. Autoimmune and granulomatous complications are more frequent than in D83.0. Wide age-of-onset distribution (10s–50s).
5. PathophysiologyFollicular helper T-cell (Tfh) dysfunction → insufficient germinal center reaction → reduced class-switched memory B cells → reduced IgG. Regulatory T-cell (Treg) deficiency/dysfunction → promotes autoimmune and inflammatory complications. A general reduction in CD4+ T cells may accompany it.
6. SymptomsShared with D83.0: recurrent bacterial pneumonia and sinusitis, bronchiectasis. D83.1 features: prominent autoimmune complications (ITP, AIHA, enteritis); granulomatous lung lesions; lymphoproliferation; higher rates of non-infectious diarrhea and malabsorption.
7. SignsReduced IgG + reduced CD4+ T cells + reduced Tfh; inverted peripheral blood CD4/CD8; autoimmune cytopenias; elevated serum LDH and ferritin (lymphoproliferation); chest CT: lung granulomas (ILD/GLD); splenomegaly.
8. ScreeningSerum IgG/A/M; T-cell fractions (CD4+/CD8+, Tfh, Treg); autoantibodies (ANA, anti-red cell, anti-platelet); ICOS/LRBA/CTLA4 genetic testing based on family history.
9. DiagnosisStandard CVID criteria (reduced IgG + poor vaccine response + age 4 or older + exclusion of secondary causes) + T-cell immunophenotype (reduced CD4, reduced Tfh, reduced Treg) + autoimmune markers + search for a single-gene cause.
10. TreatmentIgG replacement therapy (IVIG/SCIG) is the mainstay; autoimmunity: steroids, rituximab; LRBA/CTLA4 abnormalities: abatacept considered first; granulomas: steroids, azathioprine, TNF inhibitors; HSCT (considered in severe refractory cases).
11. PrognosisPoorer prognosis than D83.0 when autoimmune and granulomatous complications are present. Prognosis improves with early initiation of abatacept when LRBA/CTLA4 abnormalities are confirmed. Malignant lymphoma and pulmonary complications are the main causes of death.
12. PreventionLive vaccines contraindicated; continue IVIG; early detection and treatment of autoimmune complications; genetic counseling and family screening after a single gene is identified; monitoring for pulmonary, hepatic and intestinal complications.
13. ReferencesChapel H et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes … and 9 other papers

1. History

The history of D83.1 (common variable immunodeficiency with predominant immunoregulatory T-cell disorders) is shared with the history of CVID as a whole. The concept of CVID was established as a heterogeneous group of adult-onset hypogammaglobulinemias through the 1960s–70s after Bruton's description of agammaglobulinemia in 1953. However, the existence of a subtype within CVID in which T-cell abnormalities stand out as the main immunological feature came to be clinically recognized only with the development of immunophenotypic analysis in the 1980s–90s.

Several studies published in the 1980s observed that some CVID patients showed reduced CD4+ T-cell numbers, an inverted CD4/CD8 ratio or T-cell dysfunction. This suggested that the disease is not limited to antibody deficiency but may also be accompanied by partial impairment of cellular immunity. In the 1990s, it was confirmed that non-infectious complications such as autoimmune cytopenias, granulomatous lung lesions and lymphoproliferative complications are frequent among CVID patients, and it was gradually recognized that these complications occur more often in the group of patients with prominent T-cell abnormalities.

The 2008 EUROClass study (Wehr et al.), which systematically classified 447 CVID patients by immunophenotype, reported that increased CD21lo B cells (non-activated anergic B cells), reduced switched memory B cells and reduced Tregs are strongly associated with autoimmune and granulomatous complications. This study laid the foundation for subtyping CVID not only by B-cell classification but also in connection with markers of T-cell regulatory abnormality, and contributed to identifying a clinical group consistent with the concept of ICD-10 D83.1 (T-cell regulatory abnormality type).

In 2015–2016, it was reported that in patients with LRBA deficiency, T-cell regulatory abnormalities, loss of CTLA-4 protein and autoimmune complications are prominent, and that these complications improve dramatically with abatacept (CTLA4-Ig) (Lo et al., 2015), establishing that abnormalities of the T-cell regulatory pathway (CTLA-4/CD28) are the core pathophysiology in a particular subtype of CVID. This discovery had a decisive influence on the development of targeted therapy for the D83.1 subtype.

2. Causes

The core immunological abnormality of D83.1 is dysfunction of immunoregulatory T cells (especially follicular helper T cells [Tfh] and regulatory T cells [Treg]). Tfh cells are the key cells supporting class switching, somatic hypermutation and memory B-cell differentiation of B cells in lymphoid germinal centers, so Tfh dysfunction directly causes reduced IgG and IgA production. Treg deficiency or dysfunction leads to a breakdown of immune self-tolerance, which suppresses autoreactive T cells and B cells, causing autoimmune complications.

The best characterized causative genes are as follows. ICOS deficiency (ICOS gene, 2q33.2): ICOS is a costimulatory receptor essential for the survival and function of activated T cells, especially Tfh cells. In ICOS deficiency, Tfh cells decrease and the germinal center reaction becomes insufficient, reducing switched memory B cells and IgG production. In this case, T-cell numbers themselves also tend to decrease. LRBA deficiency (LRBA gene, 4q31.3): LRBA mediates intracellular vesicle trafficking and maintains cell-surface CTLA-4 expression by preventing lysosomal degradation of CTLA-4 protein. In LRBA deficiency, CTLA-4 is rapidly lost from the cell surface, the suppressive function of Tregs declines and proliferation of activated T cells goes unchecked. As a result, autoimmunity (ITP, AIHA, enteritis, lung granulomas), lymphoproliferation (splenomegaly, lymphadenopathy) and inflammatory complications develop.

CTLA-4 haploinsufficiency (CTLA4 gene, 2q33.2): Heterozygous loss-of-function variants of CTLA-4 reduce CTLA-4 signaling in Tregs and effector T cells, resulting in T-cell hyperactivation, autoimmunity, lymphoproliferation and hypogammaglobulinemia. It shows a clinical phenotype similar to LRBA deficiency. Heterozygous NFKB1 (19p13.3) and NFKB2 (10q24.32) variants: abnormalities of the NF-κB signaling pathway affect B-cell and T-cell development and immune regulation. They are drawing attention as important causative genes of familial CVID. In most D83.1 patients, such single-gene causes are not identified, and the disease is presumed to result from the combined action of multiple genes and environmental factors.

3. Genetics

The modes of inheritance associated with the D83.1 subtype vary according to the causative gene. ICOS deficiency and LRBA deficiency follow an autosomal recessive mode of inheritance. When both parents are carriers, there is a 25% risk of an affected child with each pregnancy. CTLA-4 haploinsufficiency has an autosomal dominant mode of inheritance, and 50% of the children of an affected parent may be affected. However, penetrance of CTLA-4 haploinsufficiency is incomplete, so the clinical phenotype varies greatly even among family members carrying the same variant. NFKB1/NFKB2 variants are also autosomal dominant and are identified in about 5–10% of familial CVID.

Several cohort studies suggest that the rate of identifying a single-gene cause in the D83.1 subtype is relatively higher than in D83.0. In CVID patients with autoimmune, granulomatous or lymphoproliferative complications, performing LRBA and CTLA4 genetic testing first helps determine the direction of treatment. In particular, confirmation of LRBA or CTLA4 variants is therapeutically important because it is an indication for abatacept treatment. With NGS panel testing or WES, many CVID-related genes such as ICOS, LRBA, CTLA4, NFKB1, NFKB2, CARD11, PIK3CD and PIK3R1 can be analyzed simultaneously.

The key points in genetic counseling are ① explaining the mode of inheritance (dominant vs recessive) according to the identified gene, ② recommending carrier testing or testing for affected status in family members (siblings, children), ③ explaining phenotypic variability due to incomplete penetrance in CTLA4 haploinsufficiency, and ④ explaining gene-specific treatment options such as abatacept.

4. General epidemiology

D83.1 is the group of patients within CVID as a whole (prevalence about 1:25,000–1:50,000) classified as the subtype in which immunoregulatory T-cell abnormalities predominate. The findings of large cohort studies (Chapel et al., 2008; Cunningham-Rundles et al.) that autoimmune complications develop in about 20–30% of CVID patients and granulomatous complications in about 10–15% suggest that this subtype, in which T-cell regulatory abnormalities predominate, accounts for a considerable portion of CVID as a whole. Specifically, the proportion of patients classified as D83.1 varies with diagnostic criteria and classification systems, but some studies estimate it at about 20–30% of all CVID.

The age of onset is very broad, ranging from the teens to the 50s, and most often patients are first diagnosed in adulthood (20s–40s) with recurrent infections or autoimmune complications. Some patients first present with autoimmune disease (ITP, AIHA), and reduced IgG is found during blood testing, leading to a diagnosis of CVID. As with the D83.0 subtype, diagnostic delay (on average 5–10 years) is an important problem in this subtype as well.

In familial CVID associated with NFKB1/NFKB2 variants, there may be multiple affected members within a family, and in CTLA4 haploinsufficiency as well, cases with T-cell regulatory abnormalities and hypogammaglobulinemia within a family have been reported. In patients with a single-gene cause (ICOS, LRBA, CTLA4 variants), autoimmune and granulomatous complications are particularly frequent, and treatment response and prognosis also show different characteristics.

5. Pathophysiology

The core pathophysiology of D83.1 is that dysfunction of immunoregulatory T cells simultaneously causes a breakdown of immune self-tolerance and failure of antibody production. Abnormalities of two main T-cell populations play a central role.

Follicular helper T-cell (Tfh) dysfunction: Tfh cells interact directly with B cells in germinal centers and support class-switch recombination, somatic hypermutation and plasma cell differentiation of B cells through ICOS-ICOSL signaling, IL-21 secretion and CD40L-CD40 interaction. In ICOS deficiency, Tfh cells fail to maintain germinal centers and the germinal center reaction itself collapses. As a result, switched memory B cells are not generated and IgG, IgA and IgM production is generally reduced. This pathophysiology is an "indirect antibody deficiency" that arises from insufficient T-cell help rather than from an abnormality of B cells themselves.

Regulatory T-cell (Treg) dysfunction: CTLA-4 signaling is essential for the suppressive function of Tregs. Normally, Tregs use CTLA-4 to remove CD80/CD86 (B7 molecules) from antigen-presenting cells (APCs) (trans-endocytosis), reducing costimulatory signals to effector T cells. In LRBA deficiency or CTLA4 haploinsufficiency, when cell-surface expression of CTLA-4 decreases and the suppressive function of Tregs declines, autoreactive effector T cells and B cells become activated without control, leading to ① autoimmune cytopenias (ITP, AIHA), ② autoimmune enteritis (CD4+ T-cell infiltration of the intestinal mucosa), ③ granulomatous inflammation of the lungs and multiple organs, and ④ lymphoproliferation (splenomegaly and lymphadenopathy, lymphocytic tissue infiltration).

Interestingly, dysfunction of immunoregulatory T cells also impairs direct T cell-dependent immune responses to B cells. Hyperactivated effector T cells may paradoxically generate excessive nonspecific inhibitory signals to B cells, interfering with the differentiation of antibody-producing B cells. These complex mechanisms explain the paradoxical phenotype in D83.1 in which antibody deficiency, autoimmunity and granulomatous complications appear simultaneously.

6. Symptoms

D83.1 is characterized by prominent autoimmune, granulomatous and lymphoproliferative complications in addition to the infectious complications it shares with D83.0.

Infectious complications: As in D83.0, recurrent bacterial pneumonia (pneumococcus, H. influenzae), chronic sinusitis and otitis media are common. IgG replacement with IVIG reduces the frequency of infections, but they often do not disappear completely. When bronchiectasis progresses, chronic airway infection persists.

Autoimmune complications are the most characteristic clinical feature of the D83.1 subtype. Immune thrombocytopenia (ITP): reduced platelet count due to autoantibodies against platelets → bleeding tendency. Autoimmune hemolytic anemia (AIHA): hemolysis due to autoantibodies on the red cell surface. Cases in which ITP and AIHA appear together (Evans syndrome) have also been reported. Autoimmune enteritis: digestive and absorptive impairment, chronic diarrhea, weight loss; mucosal ulcers on colonoscopy and villous atrophy in small bowel lesions. Differentiation from Giardia infection is needed. Autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus-like syndromes may also accompany it.

Granulomatous complications: Non-infectious granulomas occur most commonly in the lungs (granulomatous-lymphocytic interstitial lung disease, GLILD), with chronic dry cough, dyspnea and restrictive ventilatory defects. Lung CT shows nodular opacities, ground-glass opacities and hilar lymphadenopathy. Granulomas can also form in the spleen, liver, lymph nodes, skin and gastrointestinal tract. Lymphoproliferation: splenomegaly, generalized lymphadenopathy and lymphocytic infiltration of tissues are observed. Increased risk of progression to lymphoma.

7. Signs

The physical and laboratory signs of D83.1 consist of findings of hypogammaglobulinemia plus findings related to T-cell abnormalities and autoimmune and granulomatous complications.

Serum immunoglobulins: As in D83.0, IgG < 5 g/L with reduced IgA and/or IgM. Poor vaccine response.

T-cell immunophenotype: Reduced CD4+ T-cell count or reduced CD4/CD8 ratio (normal 1.5–2.5:1 → inverted). Reduced follicular helper T cells (PD-1+CXCR5+CD4+, Tfh). Reduced regulatory T cells (CD4+CD25+FOXP3+, Treg) or reduced CTLA-4 expression. Increased activated T cells (CD4+CD38+HLA-DR+).

Autoimmune-related findings: Reduced platelet count (with ITP), positive direct Coombs test (DAT) (AIHA), reduced hemoglobin + increased reticulocytes (hemolysis), autoantibodies (ANA, anti-dsDNA, anti-platelet, anti-red cell). In Evans syndrome, simultaneous reduction of platelets and blood cells.

Imaging and tissue findings: GLILD findings on chest CT (ground-glass opacities, nodular opacities, peribronchiolar nodules). Splenomegaly on splenic ultrasound/CT. On PET-CT, multiple sites of increased FDG uptake in the lungs, spleen, lymph nodes, liver, etc. (reflecting granuloma activity). Non-caseating granulomas and lymphocytic infiltration on lung tissue biopsy. Elevated serum LDH, ferritin and β2-microglobulin suggest lymphoproliferation or lymphoma.

8. Screening

Screening for the D83.1 subtype includes, in addition to common CVID screening, further assessment for T-cell abnormalities and autoimmune complications.

First-line screening: Quantification of serum IgG/A/M (common to CVID). Complete blood count (to check for autoimmune cytopenias: platelets, hemoglobin, white blood cells). Autoantibodies (ANA, anti-dsDNA, DAT, anti-platelet).

Second-line screening: T-cell fractions (flow cytometry): CD4+ T-cell count, Tfh (PD-1+CXCR5+CD4+), Treg (CD4+CD25+FoxP3+), activated T cells (CD38+HLA-DR+CD4+). CTLA-4 protein expression (flow cytometry: intracellular CTLA-4 expression in CD4+ T cells and Tregs). LRBA protein expression (flow cytometry: loss of LRBA expression in monocytes).

Family history-based screening: When CTLA4 or LRBA variants have been identified, genetic testing of family members (especially parents and children) is recommended. Screening for familial CVID in families with identified NFKB1/NFKB2 variants.

Screening for pulmonary, hepatic and lymph node complications: Baseline chest CT (to check for early GLILD findings). Liver function tests, abdominal ultrasound (hepatomegaly and splenomegaly, hepatic granulomas). LDH, β2-microglobulin (lymphoma screening).

9. Diagnosis

The diagnosis of D83.1 is made by meeting the standard CVID criteria + confirming T-cell immunological abnormalities + assessing autoimmune/granulomatous complications + searching for a single-gene cause.

Standard CVID criteria (ESID 2016): IgG ≥2 SD below + reduced IgA/IgM + poor vaccine response + after age 4 + exclusion of secondary causes.

Confirmation of T-cell immunophenotype: reduced CD4+ T-cell count or inverted CD4/CD8; reduced Tfh cells (CD4+CXCR5+PD-1+); reduced or dysfunctional Treg cells (CD4+CD25+FoxP3+); increased activated T cells (CD38+HLA-DR+CD4+).

Single-gene testing: LRBA protein expression (flow cytometry; loss of expression in monocytes strongly suggests LRBA deficiency) → LRBA gene sequencing. CTLA-4 protein expression (CTLA4 variant suspected if intracellular expression is reduced) → CTLA4 gene sequencing. NGS panel including ICOS, NFKB1, NFKB2, PIK3CD and PIK3R1. Autoimmune panel: ANA, anti-dsDNA, ANCA, DAT, anti-platelet antibodies.

Diagnosis of complications: When lung granulomas (GLILD) are confirmed, BAL (bronchoalveolar lavage) and CT-guided lung tissue biopsy. When lymphoma is suspected, PET-CT and lymph node biopsy. Gastrointestinal assessment: upper gastrointestinal endoscopy (duodenal biopsy, confirmation of villous atrophy), colonoscopy (intestinal mucosal granulomas, autoimmune enteritis).

10. Treatment

Treatment of D83.1 adds subtype-specific treatment (treatment of autoimmune and granulomatous complications, targeted therapy for single-gene causes) to the common CVID treatment (IgG replacement therapy).

IgG replacement therapy (IVIG/SCIG): the mainstay of infection prevention. Target IgG ≥700–800 mg/dL. In D83.1, a higher IgG target may be helpful when autoimmune complications are active, and high-dose IVIG also partly contributes to the treatment of autoimmune cytopenias.

Treatment of autoimmune complications: High-dose steroids (prednisolone 1–2 mg/kg/day) for initial treatment of ITP/AIHA. If steroid-refractory or steroid-dependent, rituximab (anti-CD20), azathioprine, mycophenolate mofetil (MMF), splenectomy and others are considered. When LRBA deficiency or CTLA4 haploinsufficiency is confirmed: abatacept (CTLA4-Ig) has dramatic effects on autoimmune, lymphoproliferative and intestinal complications and is considered first. Abatacept binds to CD80/86 on APCs, suppressing hyperactivation of effector T cells, and acts by supplementing CTLA-4 signaling externally.

Treatment of granulomatous complications (GLILD): Steroids (high dose → gradual tapering) alone or in combination with azathioprine or mycophenolate mofetil. Efficacy of rituximab reported for steroid-refractory granulomas. TNF-α inhibitors (infliximab) are also tried. Abatacept when LRBA/CTLA4 abnormalities are confirmed.

HSCT: HSCT is considered for severe refractory autoimmune and granulomatous complications, or in LRBA/CTLA4 abnormalities refractory to existing treatments including abatacept. In particular, in LRBA deficiency (autosomal recessive), HSCT can correct the immune defect, and good results have been reported at some centers.

11. Prognosis

The D83.1 subtype is known to have a poorer overall prognosis than D83.0 when autoimmune and granulomatous complications are present. In the cohort study by Chapel et al. (2008), the 10-year survival of CVID patients with autoimmune complications was markedly lower than that of the group without autoimmunity, and granulomatous complications were identified as an independent predictor of risk of death.

The main causes of death are ① pulmonary complications (bronchiectasis, pulmonary fibrosis and respiratory failure due to GLILD), ② non-Hodgkin lymphoma (increased tens of times compared with the general population), ③ hepatic complications (hepatic fibrosis and liver failure due to granulomas or autoimmune hepatitis) and ④ uncontrolled autoimmune complications. Several studies have confirmed that early administration of abatacept in patients with confirmed LRBA or CTLA4 abnormalities markedly improves these complications and improves prognosis.

Early diagnosis (minimizing diagnostic delay), immediate start of IgG replacement therapy, and identification of single-gene causes with early application of targeted therapy (abatacept) are key to improving the prognosis of this subtype. The role of specialized immunology clinics for long-term follow-up care is important.

12. Prevention

Prevention of D83.1 adds subtype-specific prevention of complications to the common CVID prevention principles.

Primary prevention: When a single-gene cause (LRBA, CTLA4, ICOS, NFKB1, etc.) has been identified, the risk to family members is assessed through genetic counseling, and early diagnosis and treatment of affected family members are carried out. In CTLA4 haploinsufficiency, the risk to children (50%) under autosomal dominant inheritance is explained, and PGT and prenatal diagnosis options are presented.

Secondary prevention (prevention of complications): The contraindication to live vaccines is strictly observed. Early start and continuation of IgG replacement therapy (IVIG/SCIG). When LRBA/CTLA4 abnormalities are confirmed, early administration of abatacept to prevent or delay autoimmune and granulomatous complications. When autoimmune complications develop, they are treated promptly to prevent progressive organ damage. Regular assessment of lung function (every 6–12 months, pulmonary function tests + chest CT) for early detection and treatment of GLILD.

Tertiary prevention (management of long-term complications): Lymphoma surveillance (regular measurement of LDH and β2-microglobulin, PET-CT). Regular assessment of liver function (surveillance for hepatic granulomas and autoimmune hepatitis). Prevention of osteoporosis (calcium and vitamin D, bone density testing in patients on long-term steroids). Psychosocial support: recognizing the psychological burden of chronic autoimmune and immunodeficiency disease and providing appropriate psychological counseling and links to patient support groups.


13. References

  1. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–286. DOI: 10.1182/blood-2007-11-124545. PMID: 18319398.

  2. Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85. DOI: 10.1182/blood-2007-06-091744. PMID: 17898316.

  3. Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nature Immunology. 2003;4(3):261–268. DOI: 10.1038/ni902. PMID: 12577056.

  4. Lo B, Zhang K, Lu W, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436–440. DOI: 10.1126/science.aaa1663. PMID: 26206937.

  5. Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. Journal of Allergy and Clinical Immunology. 2018;142(6):1932–1946. DOI: 10.1016/j.jaci.2018.02.055. PMID: 29571818.

  6. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clinical Immunology. 1999;92(1):34–48. DOI: 10.1006/clim.1999.4725. PMID: 10413651.

  7. Boursiquot JN, Gérard L, Malphettes M, et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. Journal of Allergy and Clinical Immunology: In Practice. 2013;1(5):575–582. DOI: 10.1016/j.jaip.2013.06.007. PMID: 24565612.

  8. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: In Practice. 2016;4(1):38–59. DOI: 10.1016/j.jaip.2015.07.025. PMID: 26563668.

  9. Seidel MG, Kindle G, Gathmann B, et al. The ESID Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(6):1763–1770. DOI: 10.1016/j.jaip.2019.02.004. PMID: 30776527.

  10. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.